MIRM vs. COLL, MNKD, PCRX, SYRE, VRNA, ABCL, BLTE, PRTA, GYRE, and IRWD
Should you be buying Mirum Pharmaceuticals stock or one of its competitors? The main competitors of Mirum Pharmaceuticals include Collegium Pharmaceutical (COLL), MannKind (MNKD), Pacira BioSciences (PCRX), Spyre Therapeutics (SYRE), Verona Pharma (VRNA), AbCellera Biologics (ABCL), Belite Bio (BLTE), Prothena (PRTA), Gyre Therapeutics (GYRE), and Ironwood Pharmaceuticals (IRWD). These companies are all part of the "pharmaceutical preparations" industry.
Mirum Pharmaceuticals (NASDAQ:MIRM) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, community ranking, valuation, risk, institutional ownership and earnings.
Mirum Pharmaceuticals currently has a consensus target price of $49.73, suggesting a potential upside of 100.92%. Collegium Pharmaceutical has a consensus target price of $39.00, suggesting a potential upside of 15.83%. Given Mirum Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Mirum Pharmaceuticals is more favorable than Collegium Pharmaceutical.
Collegium Pharmaceutical received 266 more outperform votes than Mirum Pharmaceuticals when rated by MarketBeat users. However, 72.37% of users gave Mirum Pharmaceuticals an outperform vote while only 65.16% of users gave Collegium Pharmaceutical an outperform vote.
Collegium Pharmaceutical has higher revenue and earnings than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Collegium Pharmaceutical has a net margin of 16.46% compared to Mirum Pharmaceuticals' net margin of -69.67%. Collegium Pharmaceutical's return on equity of 104.98% beat Mirum Pharmaceuticals' return on equity.
In the previous week, Collegium Pharmaceutical had 1 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 21 mentions for Collegium Pharmaceutical and 20 mentions for Mirum Pharmaceuticals. Collegium Pharmaceutical's average media sentiment score of 0.28 beat Mirum Pharmaceuticals' score of 0.22 indicating that Collegium Pharmaceutical is being referred to more favorably in the news media.
Mirum Pharmaceuticals has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500.
Summary
Collegium Pharmaceutical beats Mirum Pharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get Mirum Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MIRM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MIRM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mirum Pharmaceuticals Competitors List
Related Companies and Tools
